PMID- 12860489
OWN - NLM
STAT- MEDLINE
DCOM- 20031030
LR  - 20220311
IS  - 0149-2918 (Print)
IS  - 0149-2918 (Linking)
VI  - 25
IP  - 6
DP  - 2003 Jun
TI  - A review of rivastigmine: a reversible cholinesterase inhibitor.
PG  - 1634-53
AB  - BACKGROUND: Rivastigmine tartrate is a reversible cholinesterase inhibitor 
      indicated for the symptomatic treatment of mild to moderate dementia. It was 
      approved by the US Food and Drug Administration for the treatment of Alzheimer's 
      disease (AD) on April 21, 2000. OBJECTIVE: The purpose of this review was to 
      summarize the background on dementia of the Alzheimer type and the 
      pharmacokinetic properties, efficacy and tolerability profiles, clinical 
      applications, adverse effects (AEs), drug interactions, and pharmacoeconomics of 
      rivastigmine. METHODS: A literature search was conducted using MEDLINE 
      (1995-2002), EMBASE Geriatrics and Gerontology (1995-2002), the National 
      Institutes of Health Alzheimer's Disease Education and Resource Center Combined 
      Health Information Database, and Google. Search terms included rivastigmine, 
      Exelon, ENA 713, and ENA-713. The bibliographies of retrieved articles also were 
      searched for relevant articles. RESULTS: In clinical trials, rivastigmine has 
      improved or maintained cognitive function, global function (ie, activities of 
      daily living [ADLs]), and behavior in patients with mild to moderate AD for up to 
      52 weeks. AEs are generally mild to moderate and primarily affect the 
      gastrointestinal (GI) tract. Clinically significant drug interactions with 
      rivastigmine have thus far not been reported. Treatment with rivastigmine for up 
      to 2 years may reduce the cost of caring for patients with AD. Cost savings are 
      minimal during the first year, particularly for those with mild disease, but 
      increase during the second year of treatment. Cost savings occur earlier for 
      those with moderate AD. Most savings are realized from a delay in the need for 
      institutionalization. CONCLUSIONS: Rivastigmine has been shown to improve or 
      maintain patients' performance in 3 major domains: cognitive function, global 
      function (ADLs), and behavior. The efficacy and tolerability of rivastigmine have 
      been proved by numerous clinical trials, with the most prominent AE being GI 
      irritation.
FAU - Williams, Bradley R
AU  - Williams BR
AD  - Department of Pharmacy, University of Southern California School of Pharmacy, Los 
      Angeles, California 90089, USA.
FAU - Nazarians, Arlette
AU  - Nazarians A
FAU - Gill, Mark A
AU  - Gill MA
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Clin Ther
JT  - Clinical therapeutics
JID - 7706726
RN  - 0 (Carbamates)
RN  - 0 (Cholinesterase Inhibitors)
RN  - 0 (Phenylcarbamates)
RN  - PKI06M3IW0 (Rivastigmine)
SB  - IM
MH  - Alzheimer Disease/drug therapy/etiology/psychology
MH  - Carbamates/pharmacokinetics/*pharmacology/therapeutic use
MH  - Cholinesterase Inhibitors/pharmacokinetics/*pharmacology/therapeutic use
MH  - Clinical Trials as Topic
MH  - Cognition/drug effects
MH  - Drug Interactions
MH  - Humans
MH  - *Phenylcarbamates
MH  - Rivastigmine
RF  - 45
EDAT- 2003/07/16 05:00
MHDA- 2003/10/31 05:00
CRDT- 2003/07/16 05:00
PHST- 2003/07/16 05:00 [pubmed]
PHST- 2003/10/31 05:00 [medline]
PHST- 2003/07/16 05:00 [entrez]
AID - S0149291803801601 [pii]
AID - 10.1016/s0149-2918(03)80160-1 [doi]
PST - ppublish
SO  - Clin Ther. 2003 Jun;25(6):1634-53. doi: 10.1016/s0149-2918(03)80160-1.